Drug products: Calmuril, Canoderm®, Caress®, Curemid, Fenuril®, Fenuril®-Hydrokortison, Karbamid Evolan, Karbamid i Decubal® kräm APL, Karbamid i Essex B kräm APL, Karbamid i Essex kräm APL, Karbamid i Essex lotion APL, Karbamid i Locobase® kräm APL, Karbamid i Locobase® lotion APL, Karbamid NET, Karbasal, Karbiderm, Miniderm Duo, Monilen
ATC code: D02AE01, D02AE51, D07XA01
Substances: urea, urea (C-13), urea (C-14)
Controlled studies on differences between men and women on efficacy, safety, and pharmacokinetics for carbamide are lacking.
The main indication of carbamide preparations is moisturizing treatment of dry skin .
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of carbamide have been found.
No studies with a clinically relevant sex analysis regarding the effect of carbamide have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of carbamide have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2020-04-17
Reviewed by: Diana Rydberg, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson